LPTX - Leap Therapeutics: The DisTinGuish Trial Provides A Near-Term Catalyst

2024-05-13 10:58:13 ET

Summary

• LPTX is developing DKN-01, a drug with potential in multiple types of cancer, including colorectal, esophagogastric, and endometrial cancer.
• LPTX's DisTinGuish study looks at DKN-01 in gastric cancer and gastroesophageal cancer patients. Part C of that study is set to produce initial data in mid-2024.
• DKN-01 has further shots on goal in colorectal cancer and endometrial cancer, which could reduce downside if DisTinGuish Part C disappoints.

Leap Therapeutics ( LPTX ) is a Cambridge, Massachusetts, based biotech developing drugs for cancer. The company's drug DKN-01 is an anti-DKK1 monoclonal antibody in clinical trials for colorectal, esophagogastric and endometrial cancer. This article takes a look at DKN-01's results in esophagogastric cancer and the upcoming catalyst there....

For further details see: